Advertisement

Breast Cancer Research and Treatment

, Volume 30, Issue 3, pp 283–292 | Cite as

Oral contraceptive use and the prognosis of breast cancer

  • Ines Schönborn
  • Peter Nischan
  • Klaus Ebeling
Report

Summary

In 471 breast cancer patients the influence of a positive history of oral contraceptive (OC) use on survival was investigated. 297 (63%) patients used OCs during any period of their life and 92 (20%) used them still at the time of diagnosis. Sixty months after diagnosis OC users had a significantly increased overall survival (p = 0.037). Survival rates amounted to 79.5% and 70.3% for OC users and non-users, respectively. The effect persisted after adjustment for other prognostic factors and was mainly attributed to women who had taken OCs four years or longer (p = 0.025). Comparing the survival after a 56 months median follow-up dependent on duration of OC use (never, 1–48 months, ≥ 49 months) in subgroups of prognostic factors, the most significant influence on survival was observed among long-term users with tumors more than 2 cm in diameter (p = 0.005), with axillary node-positive tumors (1–3 nodes, p = 0.055/≥ 4 nodes, p = 0.019), and with tumors of low estrogen receptor (p = 0.015) or progesterone receptor content (p = 0.04). The difference in survival between OC users and non-users cannot be explained by the distribution of prognostic factors investigated (histological type, histological grade, tumor size, lymph node involvement, hormonal receptor content). OC users had an even higher percentage of poorly differentiated tumors (p = 0.003). These results suggest an effect of OC use on tumor biology during the preclinical phase of the disease.

Key words

breast cancer oral contraceptives prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pike M, Henderson BE, Casagrande JT, Rosario I, Gray GE: Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 43: 72–76, 1981Google Scholar
  2. 2.
    McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M: Early oral contraceptive use and breast cancer: Results of another case-control study. Br J Cancer 56: 653–660, 1987Google Scholar
  3. 3.
    Olssen H: Oral contraceptives and breast cancer. A review. Acta Oncol 28: 849–863, 1989Google Scholar
  4. 4.
    Stanford JL, Brinton LA, Hoover RN: Oral contraceptives and breast cancer: results from an expanded case control study. Br J Cancer 60: 375–381, 1989Google Scholar
  5. 5.
    Vessey MP, McPherson K, Villard Mackintosh L, Yeates D: Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 59(4): 613–617, 1989Google Scholar
  6. 6.
    Harris RE, Zang EA, Wynder EL: Oral contraceptives and breast cancer risk: a case-control study. Int J Epidemiol 19: 240–246, 1990Google Scholar
  7. 7.
    Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D: Mortality among oral contraceptive users: 20 year follow-up of women in a cohort study. Br Med J 299: 1487–1491, 1989Google Scholar
  8. 8.
    Lees AW, Heather JJ, May CL, Cherian G, Lam EWH, Hanson J: Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 13: 143–151, 1989Google Scholar
  9. 9.
    Ranstam J, Olsson H, Garne JP, Aspergen K, Janzon L: Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Research 11: 2043–2046, 1991Google Scholar
  10. 10.
    WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Breast cancer and combined oral contraceptives: results from a multinational study. Br J Cancer 61: 110–119, 1990Google Scholar
  11. 11.
    Ebeling K, Ray R, Nischan P, Thomas DB, Kunde D, Stalsberg H: Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study. Br J Cancer 63: 804–808, 1991Google Scholar
  12. 12.
    WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Br Med J 290: 961–965, 1985Google Scholar
  13. 13.
    Nischan P, Ebeling K, Thomas DB, Hirsch U: Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 138: 697–703, 1993Google Scholar
  14. 14.
    World Health Organisation; Histological typing of breast tumors. 2nd ed, WHO, Geneva, 1981Google Scholar
  15. 15.
    Bloom HJG, Richardson WW: Histological grading and prognosis of breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377, 1957Google Scholar
  16. 16.
    Schönborn I, Minguillon C, Möhner M, Ebeling K: PCNA as a potential prognostic factor in breast cancer. The Breast, in press, 1994Google Scholar
  17. 17.
    Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958Google Scholar
  18. 18.
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39, 1977Google Scholar
  19. 19.
    Cox DR: Regression models and life tables. J R Stat Soc 34: 187–220, 1972Google Scholar
  20. 20.
    Donegan WL, Perez-Meza EM: Lobular carcinoma - an indication for elective biopsy of the second breast. Amer Surg 176: 178–185, 1972Google Scholar
  21. 21.
    Fisher ER, Taylor M: Changing patterns of some pathologic parameters of mammary carcinomas. Cancer 32: 1380–1391, 1973Google Scholar
  22. 22.
    Martinez V, Azzopardi JG: Invasive lobular carcinoma of the breast: incidence and variations. Histopathol 3: 467–488, 1979Google Scholar
  23. 23.
    Rosen PP, Ashikari R, Thaler H, Ishikawa S, Hirota T, Abe O, Yamamoto H, Beattie EJ, Urban JA, Mike V: A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan, and New York, USA. Cancer 39: 429–434, 1977Google Scholar
  24. 24.
    Correa P, Johnson WD: International variation in the histology of breast carcinoma. UICC Techn Rep Series 35: 36–65, 1978Google Scholar
  25. 25.
    Black WC, Bordin GM, Varsa E, Herman D: Histologic comparison of mammary carcinomas among a population of Southwestern American Indian, Spanish American, and Anglo women. Amer J Clin Pathol 71: 142–145, 1979Google Scholar
  26. 26.
    Stalsberg H, Thomas DB, Noonan EA, and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Int J Cancer 44: 399–409, 1989Google Scholar
  27. 27.
    Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL: Epidermal growth factor (EGF); results of a 6 year follow-up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 63: 146–150, 1991Google Scholar
  28. 28.
    Lipponen P, Aaltoma S, Eskelinen M, Kosma VM, Marin S, Syrjänen K: The changing importance of prognostic factors in breast cancer during long-term follow-up. Int J Cancer 51: 698–702, 1992Google Scholar
  29. 29.
    Chevallier B, Heintzmann F, Mosseri V, Dauce JP, Bastit Ph, Graic Y, Brunelle Ph, Basuyau JP, Comoz M, Asselain B: Prognostic value of estrogen and progesteron receptors in operable breast cancer. Cancer 62: 2517–2524, 1988Google Scholar
  30. 30.
    Kamby C, Rasmussen BB, Kristensen B: Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 60: 252–257, 1989Google Scholar
  31. 31.
    Donegan W: Prognostic factors, stage and receptor status in breast cancer. Cancer 70: 1755–1764, 1992Google Scholar
  32. 32.
    Eskelinen M, Lipponen P, Papinaho S, Aaltoma S, Kosma VM, Klemi P, Syrjänen K: DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 51: 555–561, 1992Google Scholar
  33. 33.
    Vessey MP, Doll R, Jones K, McPherson K, Yeates D: An epidemiological study of oral contraceptives and breast cancer. Br Med J 1: 1755–1758, 1979Google Scholar
  34. 34.
    Matthews PhN, Millis RR, Hayward JL: Breast cancer in women who have taken contraceptive steroids. Br Med J 282: 774–776, 1981Google Scholar
  35. 35.
    Rosner D, Lane WW, Brett RP: Influence of oral contraceptives on the prognosis of breast cancer in young women. Cancer 55: 1556–1562, 1985Google Scholar
  36. 36.
    Rosner D, Lane WW: Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer 57: 591–596, 1986Google Scholar
  37. 37.
    Spencer JD, Millis RR, Hayward JL: Contraceptive steroids and breast cancer. Br Med J 1: 1024–1026, 1978Google Scholar
  38. 38.
    Schönborn I, Zschiesche W, Spitzer E, Minguillon C, Möhner M, Grosse R, Ebeling K: C-erbB-2 protein overexpression in primary breast cancer: independent factor in patients at high risk. Breast Cancer Res Treat: in press, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Ines Schönborn
    • 1
  • Peter Nischan
    • 2
  • Klaus Ebeling
    • 3
  1. 1.Department of Obstetrics and GynecologyUniversity Hospital ‘Rudolf Virchow’, Freie Universität BerlinGermany
  2. 2.Department of Epidemiology and Social MedicineMedical School HannoverGermany
  3. 3.Berlin-Nieder-schönhausenGermany

Personalised recommendations